Provided by Tiger Trade Technology Pte. Ltd.

SINOMAB BIO-B

2.030
+0.0301.50%
Volume:7.46M
Turnover:14.95M
Market Cap:2.82B
PE:-11.77
High:2.050
Open:2.020
Low:1.960
Close:2.000
52wk High:3.760
52wk Low:1.000
Shares:1.39B
HK Float Shares:1.39B
Volume Ratio:0.91
T/O Rate:0.54%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.172
ROE:-55.49%
ROA:-9.91%
PB:10.20
PE(LYR):-11.77
PS:433.16

Loading ...

SINOMAB BIO-B Shares Surge Over 5% Again as SM17 Preclinical Study Shows Strong Potential for CRSwNP and IPF Treatment

Stock News
·
Feb 20

No Products Secured Billion-Dollar Orders, Qiang Jing's Wife Cashed Out Before Sinovant's IPO

Deep News
·
Jan 05

Major IPO Update: Former CICC Research MD Leads Suzhou InnovaBio's Rapid Listing Acceptance on STAR Market

Deep News
·
Dec 24, 2025

BRIEF-Sinomab Bioscience Says IND Application For SM17 Accepted By NMPA CDE

Reuters
·
Dec 11, 2025

SinoMab BioScience Inflammatory Bowel Disease Drug Application Accepted in China

MT Newswires Live
·
Dec 11, 2025

SINOMAB BIO-B (03681): SM17 New Drug Research Application Accepted by NMPA's CDE

Stock News
·
Dec 11, 2025

SinoMab BioScience Ltd - Ind Application for SM17 Accepted by Nmpa Cde

THOMSON REUTERS
·
Dec 11, 2025

SINOMAB BIOSCIENCE LIMITED (03681) Releases November 2025 Monthly Return

Bulletin Express
·
Dec 04, 2025

10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled

Stock News
·
Dec 03, 2025

Hong Kong Stock Market Preview | International Gold Prices Reach New Historic High, Powell Signals Potential End to Balance Sheet Reduction

Stock News
·
Oct 15, 2025

SinoMab BioScience Doses First Group of Patients in Atopic Dermatitis Drug Study

MT Newswires Live
·
Oct 14, 2025

SINOMAB BIO-B (03681): SM17 Subcutaneous Injection Bridging Study in China Completes First Cohort Dosing in Healthy Subjects

Stock News
·
Oct 14, 2025

SinoMab BioScience Announces Successful Dosing of First Cohort in Bridging Study of Subcutaneous SM17 in China

Reuters
·
Oct 14, 2025

SINOMAB BIO-B (03681): Lai Weiqi Appointed as Company Secretary

Stock News
·
Oct 08, 2025

SinoMab BioScience Appoints Lai Florence Wai Ki as New Company Secretary Replacing Chow Yuk Yin Ivy

Reuters
·
Oct 08, 2025

Core Pipeline Breakthroughs Highlight Autoimmune Expertise as SINOMAB BIO-B (03681) Drives Innovation-Led Growth

Stock News
·
Sep 04, 2025

Hong Kong Stock Alert | SINOMAB BIO-B (03681) Surges Over 15% on Significant Clinical Trial and Pipeline Development Progress, First-Half Revenue Reaches RMB 9.802 Million

Stock News
·
Sep 03, 2025

SINOMAB BIO-B (03681) Reports Interim Results with RMB 32.74 Million R&D Costs as Two Core Drug Pipelines Achieve Breakthrough Progress

Stock News
·
Aug 29, 2025

SinoMab BioScience H1 Net Income RMB -49.8 Million

THOMSON REUTERS
·
Aug 29, 2025

SINOMAB BIO-B (03681) Completes Issuance of 24.97 Million Subscription Shares

Stock News
·
Aug 29, 2025